The analysts might have been a bit too bullish on Akzo Nobel N.V. (AMS:AKZA), given that the company fell short of expectations when it released its quarterly results last week. Akzo Nobel missed earnings this time around, with €2.7b revenue coming in 2.6% below what the analysts had modelled. Statutory earnings per share (EPS) of €0.95 also fell short of expectations by 19%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for Akzo Nobel

Taking into account the latest results, the current consensus from Akzo Nobel's 17 analysts is for revenues of €11.0b in 2025. This would reflect a credible 3.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to soar 24% to €4.11. Yet prior to the latest earnings, the analysts had been anticipated revenues of €11.0b and earnings per share (EPS) of €4.10 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

There were no changes to revenue or earnings estimates or the price target of €73.47, suggesting that the company has met expectations in its recent result. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Akzo Nobel at €91.00 per share, while the most bearish prices it at €58.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Akzo Nobel's past performance and to peers in the same industry. We would highlight that Akzo Nobel's revenue growth is expected to slow, with the forecast 2.8% annualised growth rate until the end of 2025 being well below the historical 4.9% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 4.3% per year. Factoring in the forecast slowdown in growth, it seems obvious that Akzo Nobel is also expected to grow slower than other industry participants.